By Invesco : By Janet Luby Part 1: A Biotech/Pharma Revolution This is the first in a four-part series examining dynamic and durable growth themes that affect the U.S. economy and may present opportunities for investors. The remaining three blog posts will examine the enormous implications of shale
players in the sector by buying ETFs, such as the SPDR S & P Biotech ETF (NY XBI ) and the iShares Nasdaq Biotechnology (NASDAQ: IBB ) with our preference being the SPDR S & P Biotech due to it having less exposure to the more speculative
By DoctoRx : Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed. Biogen Idec (NASDAQ: BIIB ) fell more than 7% after that statement. Gilead Sciences (NASDAQ: GILD ) fell 5% peak-to-trough. Small ones got dumped big-time. Is it but a passing ...
which led March's "momo" selloff, among them the biotechs ( XBI -4.5% ) and social media ( SOCL -4.4% ). Also familiar ..... and he suggests investors begin raising cash. Biotech ETFs: XBI , BBH , FBT , PBE Low-vol ETFs: SPLV , LGLV , CFA , CFO Utility
had a huge impact on the SPDR Biotech ETF ( XBI ), which rose more than 6% that day. Because XBI is a modified equal-weighted index, IDIX ..... represented just 1.5% of the underlying holdings in XBI , but the recent jump has catapulted its total
By Rod Raynovich : Rally Retraces Correction Up To Mid-Point YTD Up until this week, we have focused on large cap biopharmaceuticals because of revenue momentum, fair valuations and earnings. A risk-off sentiment due to lack of ASCO buzz and the Q1 speculative bubble downdraft has curbed gains. ...
A potentially good idea gone bad - Short-structured ETFs This analysis is prompted by the intense, but partially-knowledgeable comment-response of another Seeking Alpha reader to my recent article advocating the iShares Nasdaq Biotechnology ETF ( IBB ) as a defensive investment. This article in ...
with more small- and mid-cap exposure like the SPDR S & P Biotech ETF ( XBI +5.7% ) and the PowerShares Dynamic Biotechnology ..... PBE +7.4% ) are partying. It also turns out the XBI and PBE are the two largest holders of Idenix stock
By Morningstar : By Robert Goldsborough The U.S. biotechnology sector has enjoyed an impressive run during the past decade. The industry has dramatically outperformed the broader market over that time frame and also had a tremendous 2013. Large-cap biotech firms have fueled this rally, as they have
tracking other health-care subsectors show numbers in the 20% to 25% range. For instance, the equal-weight SPDR S & P Biotech XBI has a five-year volatility of return of 24.5%. Meanwhile, the market-cap-weighted iShares US Healthcare